Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice

Aim. To evaluate the structure of multimorbidity, outcomes and the potential effect of dapagliflozin in patients with a combination of cardiovascular disease (CVD) and type 2 diabetes in Russian clinical practice.

Material and methods. The data of 10 registries with the inclusion of 22957 people, including 4370 with type 2 diabetes in 6 regions of the Russian Federation, were analyzed. Scenarios for reducing mortality from all and cardiovascular causes and hospitalizations for CVD were simulated among groups of patients with diabetes combined with myocardial infarction (MI) and diabetes combined with heart failure with reduced ejection fraction (HFrEF) based on data from the Federal Registry of diabetes, the RECVASA and REGION registries, relative risks associated with analyzed adverse events from the DECLARE study.

Results. When analyzing the data of all 22957 patients with CVD included in the registries, it was found that the proportion of patients with comorbid diabetes was on average 19.0%. Of the various diagnoses of CVD, the combination with diabetes was most often recorded in patients that had MI – 2.0%, stroke – 22.5% and heart failure – 24.0%. In the RECVASA registry (Ryazan) for 4 years of follow-up of 699 patients with a combination of CVD and diabetes mortality from all causes was 20.9%, and from cardiovascular causes – 15.6%. The simulated number of potentially prevented cardiovascular deaths with dapagliflozin taking in patients with diabetes combined with MI for 4 years in Russia will be 39124, and 37440 cardiovascular hospitalizations. The number of potentially preventable deaths from all causes among patients with diabetes combined with HFrEF will be 4543, cardiovascular deaths in 1995, and the number of prevented cardiovascular hospitalizations will be 7072.

Conclusion. According to data from the registries of CVD patients in 6 regions of the Russian Federation, it was revealed that in real clinical practice the proportion of people with comorbid diabetes averaged 19% both at the outpatient and hospital stages. These subgroups of multimorbid patients have both the highest risk of developing fatal and non-fatal cardiovascular complications, and the largest number of indications for prescribing drugs that affect the prognosis due to effects on both CVD and diabetes.

1. Bertoluci M.C., Rocha V.Z. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25. DOI:10.1186/s13098-017-0225-1.

2. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315-81. DOI:10.1093/eurheartj/ehw106.

3. Cardiovascular prevention 2017. National guidelines. Russ J Cardiol. 2018; 23(6):7-122 (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122.

4. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-12 (In Russ.) DOI:10.14341/DM2004116-17.

5. Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus. 2017;20(1):13-41 (In Russ.) DOI:10.14341/DM8664.

6. Luitse M.J.A., Biessels G.J., Rutten G., et al. Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol. 2012;11:261-71. DOI:10.1016/S1474-4422(12)70005-4.

7. Pasternak B., Ueda P., Eliasson B., et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019;366:l4772. DOI:10.1136/bmj.l4772.

8. International Diabetes Atlas, 2017. 8th edition [cited by Oct 20, 2019]. Available from: http://www.diabetesatlas.org.

9. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017 [cited by Oct 20, 2019]. Available from: http://www.cdc.gov/diabetes/data/statistics/statistics-report.html.

10. Bath P.M.W., Appleton J.P., Beridze M. Baseline characteristics of the 3096 patients recruited into the “Triple Antiplatelets for Reducing Dependency after Ischemic Stroke” trial. International Journal of Stroke. 2017;12(5):524-38. DOI:10.1177/1747493016677988.

11. Echouffo-Tcheugui J.B., Xu H., Matsouaka R.A. Diabetes and long-termoutcomes of ischaemic stroke: findings from Get with The Guidelines-Stroke. Eur Heart J. 2018;39(25):2376-86. DOI:10.1093/eurheartj/ehy036.

12. Wiviott S.D., Raz I., Bonaca M.P. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347-57. DOI:10.1056/NEJMoa1812389.

13. Boytsov S.A., Martsevich S.Y., Kutishenko N.P., et al. Registries in cardiology: their principles, rules, and real-word potential. Cardiovascular Therapy and Prevention. 2013;12(1):4-9 (In Russ.) DOI:10.15829/1728-8800-2013-1-4-9.

14. Bhatt D.L., Eagle K.A., Ohman E.M., et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010;304(12):1350-57. DOI:10.1001/jama.2010.1322.

15. Schaan B.D., Neto J., Moreira L.B., et al. Diabetes and cardiovascular events in high-risk patients: Insights from a multicenter registry in a middle-income country. Diabetes Research and Clinical Practice. 2017;127:275-84. DOI:10.1016/j.diabres.2017.03.021.

16. Bednarski J., Cieszewska E., Strzelecki A., et al. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland. Kardiol Pol. 2013;71(12):1260-5. DOI:10.5603/KP.a2013.0179.

17. Arnold S.V., Inzucchi S.E.,Tang F., et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR_ Research to Practice project. European Journal of Preventive Cardiology. 2017;24(15):1637-45. DOI:10.1177/2047487317729252.

18. Loukianov M.M., Yakushin S.S., Martsevich S.Y., et al. Cardiovascular Diseases and Drug Treatment in Patients with the History of Cerebral Stroke: Data of the Outpatient Registry REGION. Ration Pharmacotherapy in Cardiology. 2018;14(6):879-86 (In Russ.) DOI:10.20996/1819-6446-2018-14-6-879-886.

19. Martsevich S.Y., Kutishenko N.P., Lukyanov M..M, et al. The study Hospital register of patients with acute cerebrovascular accident (REGION): characteristics of patient and outcomes of hospital treatment. Cardiovascular Therapy and Prevention. 2018;17(6):32-8 (In Russ.) DOI:10.15829/1728-8800-2018-6-32-38.

20. Loukianov M.M., Boytsov S.A., Yakushin S.S., et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014;10(4):366-77. (In Russ.) DOI:10.20996/1819-6446-2014-10-4-366-377.

21. Loukianov M.M., Martsevich S.Y., Yakushin S.S., et al. The Control of International Normalised Ratio in Patients with Atrial Fibrillation Treated with Warfarin in Outpatient and Hospital Settings: Data from RECVASA Registries. Rational Pharmacotherapy in Cardiology. 2018;14(1):34-40 (In Russ.) DOI:10.20996/1819-64462018-14-1-34-40.

22. Ng C.S., Lee J.Y.C., Toh M., et al. Cost-of-illness studies of diabetes mellitus: A systematic review. Diabetes Res Clin Pr. 2014;105(2):151-63. DOI:10.1016/j.diabres.2014.03.020.

23. Seuring T., Archangelidi O., Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmaco Economics. 2015;33(8):811-31. DOI:10.1007/s40273-015-0268-9.

24. Dedov I.I. Diabetes mellitus as an economic problem in the Russian Federation. Diabetes Mellitus. 2016;19(1):30-43 (In Russ.)

25. Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Diabetes mellitus in the Russian Federation: prevalence, incidence, mortality, carbohydrate metabolism parameters and structure of hypoglycemic therapy according to the Federal Register of Diabetes Mellitus. Status 2017. Diabetes Mellitus. 2018;21(3):14459 (In Russ.) DOI:10.14341/DM9686.

26. Martsevich S.Y., Zakharova N.A., Kutishenko N.P., et al. Practice of prescribing beta-blockers and its compliance with clinical guidelines according to two registers of cardiovascular diseases. Rational Pharmacotherapy in Cardiology 2016;12(3):260-4 (In Russ.) DOI:DOI:10.20996/1819-6446-2016-12-3-260-264.

27. Kotova E.Y., Mashin V.V. Epidemiology and major risk factors for the development of stroke in Ulyanovsk (according to the register of stroke). Ulyanovsk Medico-biological Journal. 2011;2:1007 (In Russ.)

28. Chugunova S.A., Nikolaeva T.Y., Kuzmina Z.M., et al. Stroke epidemiology in Yakutsk based on the population-based register in 2015. Far East Medical Journal. 2017;3:80-5 (In Russ.)

29. Dauriz M., Mantovani A., Bonapace S., et al. Prognostic Impact of Diabetes on Long-term Survival Outcomes in Patients With Heart Failure: A Meta-analysis. Diabetes Care. 2017;40:1597-605. DOI:10.2337/dc17-0697.

30. Furtado R.H.M., Bonaca M.P., Raz I., et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019;139(22):251627. DOI:10.1161/CIRCULATIONAHA.119.039996.

31. Kato E.T., Silverman M.G., Mosenzon O., et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139:2528-36. DOI:10.1161/CIRCULATIONAHA.119.040130.